

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1656

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

|      |    |        |   |
|------|----|--------|---|
| NEWS | 1  |        | Web Page for STN Seminar Schedule - N. America  |
| NEWS | 2  | APR 04 | STN AnaVist, Version 1, to be discontinued  |
| NEWS | 3  | APR 15 | WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats                                     |
| NEWS | 4  | APR 28 | EMBASE Controlled Term thesaurus enhanced   |
| NEWS | 5  | APR 28 | IMSRESEARCH reloaded with enhancements  |
| NEWS | 6  | MAY 30 | INPAFAMDB now available on STN for patent family searching  |
| NEWS | 7  | MAY 30 | DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option                                   |
| NEWS | 8  | JUN 06 | EPFULL enhanced with 260,000 English abstracts  |
| NEWS | 9  | JUN 06 | KOREAPAT updated with 41,000 documents  |
| NEWS | 10 | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications                           |
| NEWS | 11 | JUN 19 | CAS REGISTRY includes selected substances from web-based collections  |
| NEWS | 12 | JUN 25 | CA/CAPLUS and USPAT databases updated with IPC reclassification data  |
| NEWS | 13 | JUN 30 | AEROSPACE enhanced with more than 1 million U.S. patent records   |
| NEWS | 14 | JUN 30 | EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations    |
| NEWS | 15 | JUN 30 | STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in                                      |
| NEWS | 16 | JUN 30 | STN AnaVist enhanced with database content from EPFULL  |
| NEWS | 17 | JUL 28 | CA/CAPLUS patent coverage enhanced  |
| NEWS | 18 | JUL 28 | EPFULL enhanced with additional legal status information from the epoline Register                            |
| NEWS | 19 | JUL 28 | IFICDB, IFIPAT, and IFIUDB reloaded with enhancements   |
| NEWS | 20 | JUL 28 | STN Viewer performance improved   |
| NEWS | 21 | AUG 01 | INPADOCDB and INPAFAMDB coverage enhanced   |
| NEWS | 22 | AUG 13 | CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998                                 |
| NEWS | 23 | AUG 15 | CAOLD to be discontinued on December 31, 2008   |
| NEWS | 24 | AUG 15 | CAplus currency for Korean patents enhanced   |
| NEWS | 25 | AUG 25 | CA/CAPLUS, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching           |
| NEWS | 26 | AUG 27 | CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information |
| NEWS | 27 | SEP 18 | Support for STN Express, Versions 6.01 and earlier, to be discontinued  |

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:14:22 ON 22 SEP 2008

=> File Medline EMBASE Biosis Caplus  
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL   |
|------------|---------|
| ENTRY      | SESSION |
| 0.21       | 0.21    |

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 14:14:35 ON 22 SEP 2008

FILE 'EMBASE' ENTERED AT 14:14:35 ON 22 SEP 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:14:35 ON 22 SEP 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 14:14:35 ON 22 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> S (common gamma chain) or (gammac)  
L1 2267 (COMMON GAMMA CHAIN) OR (GAMMAC)

=> S (NF-kappaB inducing kinase) or (NF-kappaBeta inducing kinase) or (NIK) or (NF-kappa B inducing kinase) or (NF-kappa Beta inducing kinase) or (NF-kB inducing kinase) or (NF-kBeta inducing kinase) or (NF-k B inducing kinase) or (NF-k Beta inducing kinase)

L2 2757 (NF-KAPPAB INDUCING KINASE) OR (NF-KAPPABETA INDUCING KINASE) OR (NIK) OR (NF-KAPPA B INDUCING KINASE) OR (NF-KAPPA BETA INDUCING KINASE) OR (NF-KB INDUCING KINASE) OR (NF-KBETA INDUCING KINASE) OR (NF-K B INDUCING KINASE) OR (NF-K BETA INDUCING KINASE)

=> S L1 (8A) L2

L3 2 L1 (8A) L2

=> d l3 1-2 bib ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2003:837297 CAPLUS  
DN 139:312400

TI Modulation of NIK with IL-2 common .gamma.  
chain and therapeutic uses thereof

IN Wallach, David; Ramakrishnan, Parameswaran; Shmushkovich, Taisia

PA Yeda Research and Development Co.Ltd, Israel  
 SO PCT Int. Appl., 98 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| PI WO 2003087380  | A1   | 20031023 | WO 2003-IL317   | 20030415 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, IJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |
| CA 2482387  | A1   | 20031023 | CA 2003-2482387 | 20030415 |
| AU 2003226607   | A1   | 20031027 | AU 2003-226607  | 20030415 |
| EP 1499729  | A1   | 20050126 | EP 2003-746399  | 20030415 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |          |
| JP 2005530491   | T    | 20051013 | JP 2003-584319  | 20030415 |
| US 20050272633  | A1   | 20051208 | US 2005-511314  | 20050517 |
| PRAI IL 2002-149217   | A    | 20020418 |                 |          |
| IL 2002-152183  | A    | 20021008 |                 |          |
| WO 2003-IL317   | W    | 20030415 |                 |          |

AB This invention relates to the use of NIK and related mols. for the modulation of signal activities controlled by cytokines, and some new such mols. In addition the invention relates to the use of a DNA encoding NIK, or its antisense, NIK specific antibodies, a small mol. obtainable by screening products of combinatorial chemical in a luciferase system, for modulating the interaction between IL-2 common gamma chain (cyc) and NIK. The present invention also relates to the use of NIK or a mutein, variant, fusion protein, functional derivative, circularly permuted derivative or fragment thereof, in the manufacture of a medicament for the treatment of a disease, wherein a cytokine stimulating signalling through the IL-2 cyc is involved in the pathogenesis of the disease.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:837291 CAPLUS  
 DN 139:328743  
 TI Modulating interaction of IL-2 with NIK by derivatives of the IL-2 common gamma chain, and therapeutic uses thereof  
 IN Wallach, David; Ramakrishnan, Parameswaran; Shmushkovich, Taisia  
 PA Yeda Research and Development Co. Ltd., Israel  
 SO PCT Int. Appl., 103 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

| PATENT NO.       | KIND | DATE     | APPLICATION NO. | DATE     |
|------------------|------|----------|-----------------|----------|
| PI WO 2003087374 | A1   | 20031023 | WO 2003-IL316   | 20030415 |

WO 2003087374 A9 20050127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2482718 A1 20031023 CA 2003-2482718 20030415

AU 2003222415 A1 20031027 AU 2003-222415 20030415

EP 1499724 A1 20050126 EP 2003-717504 20030415

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005525113 T 20050825 JP 2003-584315 20030415

US 20050287144 A1 20051229 US 2005-511722 20050622

US 7416730 B2 20080826

PRAI IL 2002-149217 A 20020418

IL 2002-152183 A 20021008

WO 2003-IL316 W 20030415

AB This invention relates to the use of IL-2 common gamma chain (cyc) and related mols. for the modulation of signal activities controlled by cytokines, and therapeutic uses thereof. Specifically, the invention relates to the use of IL-2 cyc or a mutein, variant, fusion protein, the intracellular domain of cyc (ICDcyc), 1-357, 1-341 functional derivative, circularly permuted derivative or fragment thereof for modulating the interaction between cyc and NIK. In addition the invention relates to the use of a DNA encoding cyc or derivs., a DNA encoding the antisense of cyc, an antibody specific to cyc, or a small mol. obtainable by screening products of combinatory chemical in a luciferase system, for modulating the interaction between IL-2 common gamma chain (cyc) and NIK.  
. In another aspect, the invention provides the use of cyc or derivs. in the manufacture of a medicament for treatment of a disease, wherein NIK activity is involved in the pathogenesis of the disease.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT